Gene therapy: Therapeutic gene causing lymphoma

@article{Woods2006GeneTT,
  title={Gene therapy: Therapeutic gene causing lymphoma},
  author={N. Woods and Virginie Bottero and M. Schmidt and C. Kalle and I. Verma},
  journal={Nature},
  year={2006},
  volume={440},
  pages={1123-1123}
}
  • N. Woods, Virginie Bottero, +2 authors I. Verma
  • Published 2006
  • Biology, Medicine
  • Nature
    • The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    277 Citations
    Highly Influencial Citations
    3
    Background Citations
    70
    Methods Citations
    4
    Results Citations
    5
    277 Citations
    Citation Type

    Citation Type

    Gene therapy: Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply)
    • 4
    Assessing the risk of T-cell malignancies in mouse models of SCID-X1.
    • B. Sorrentino
    • Biology, Medicine
    • Molecular therapy : the journal of the American Society of Gene Therapy
    • 2010
    • 6
    [Gene therapy of SCID-X1].
    • 6
    Gene Therapy for SCID
    Gene therapy for primary immunodeficiencies.
    • A. Thrasher
    • Medicine
    • Immunology and allergy clinics of North America
    • 2008
    • 10
    Safer vectors for gene therapy of primary immunodeficiencies.
    • 3
    • PDF
    Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
    • 23
    • PDF
    Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency 1
    • Setor de Vetores Virais
    • 2007
    • PDF
    Combating oncogene activation associated with retrovirus-mediated gene therapy of X-linked severe combined immunodeficiency
    • 2
    • PDF
    New insights and unresolved issues regarding insertional mutagenesis in X-linked SCID gene therapy.
    • 95

    References

    SHOWING 1-10 OF 12 REFERENCES
    LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
    • 3,269
    Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
    • 1,069
    Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach.
    • 76
    Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy.
    • 61
    Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice.
    • 20
    • PDF
    In vivo competitive studies between normal and common gamma chain-defective bone marrow cells: implications for gene therapy.
    • 17
    The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice.
    • 90
    Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer.
    • 95
    Lentivirus Vector-Mediated Hematopoietic Stem Cell Gene Transfer of Common Gamma-Chain Cytokine Receptor in Rhesus Macaques
    • 75
    • PDF
    Retroviral marking of canine bone marrow: long-term, high-level expression of human interleukin-2 receptor common gamma chain in canine lymphocytes.
    • 32